Search research articles
Contact Us
Filters
Showing results (1-10 of 33) with videos related to
Page
of 4
Sort By:
Anti-Cancer Drugs
|
September 14, 2021
Sensitivity of eight types of ALK fusion variant to alectinib in ALK-transformed cells
Koh Furugaki, Naoki Harada, Yasushi Yoshimura
Seishin Shinkeigaku Zasshi = Psychiatria Et Neurologia Japonica
|
December 3, 2003
[Reversible choreoathetosis associated with lithium intoxication]
Ken Wada, Takanobu Sasaki, Yasushi Yoshimura, et al.
British Journal of Haematology
|
June 28, 2022
The molecular rationale for the combination of polatuzumab vedotin plus rituximab in diffuse large B-cell lymphoma
Natsumi Kawasaki, Yukari Nishito, Yasushi Yoshimura, et al.
Cancer Biology & Therapy
|
August 25, 2020
Enhanced antitumor effect of alectinib in combination with cyclin-dependent kinase 4/6 inhibitor against <i>RET</i>-fusion-positive non-small cell lung cancer cells
Takaaki Fujimura, Koh Furugaki, Naoki Harada, et al.
Leukemia & Lymphoma
|
August 7, 2023
Efficacy of retreatment with polatuzumab vedotin in combination with rituximab in polatuzumab vedotin-resistant DLBCL models
Natsumi Kawasaki, Mayu Tomita, Yoriko Yamashita-Kashima, et al.
Cancer Chemotherapy and Pharmacology
|
February 6, 2016
Antitumor activity of alectinib, a selective ALK inhibitor, in an ALK-positive NSCLC cell line harboring G1269A mutation: Efficacy of alectinib against ALK G1269A mutated cells
Yasushi Yoshimura, Mitsue Kurasawa, Keigo Yorozu, et al.
BMC Cancer
|
April 5, 2019
Expression of C-terminal ALK, RET, or ROS1 in lung cancer cells with or without fusion
Koh Furugaki, Marie Mochizuki, Mirei Kohno, et al.
Molecular Cancer Therapeutics
|
April 14, 2021
Obinutuzumab in Combination with Chemotherapy Enhances Direct Cell Death in CD20-Positive Obinutuzumab-resistant Non-Hodgkin Lymphoma Cells
Takaaki Fujimura, Yoriko Yamashita-Kashima, Natsumi Kawasaki, et al.
Journal of Clinical Psychopharmacology
|
September 16, 2006
Manic/hypomanic switch during acute antidepressant treatment for unipolar depression
Ken Wada, Takanobu Sasaki, Hiroaki Jitsuiki, et al.
NPJ Precision Oncology
|
October 25, 2023
FGFR blockade inhibits targeted therapy-tolerant persister in basal FGFR1- and FGF2-high cancers with driver oncogenes
Koh Furugaki, Takaaki Fujimura, Hayato Mizuta, et al.
Page
of 4
Search research articles
Search
Showing results (1-10 of 33) with videos related to
Sort By:
Page
of 4
Anti-Cancer Drugs
|
September 14, 2021
Sensitivity of eight types of ALK fusion variant to alectinib in ALK-transformed cells
Koh Furugaki, Naoki Harada, Yasushi Yoshimura
Seishin Shinkeigaku Zasshi = Psychiatria Et Neurologia Japonica
|
December 3, 2003
[Reversible choreoathetosis associated with lithium intoxication]
Ken Wada, Takanobu Sasaki, Yasushi Yoshimura, et al.
British Journal of Haematology
|
June 28, 2022
The molecular rationale for the combination of polatuzumab vedotin plus rituximab in diffuse large B-cell lymphoma
Natsumi Kawasaki, Yukari Nishito, Yasushi Yoshimura, et al.
Cancer Biology & Therapy
|
August 25, 2020
Enhanced antitumor effect of alectinib in combination with cyclin-dependent kinase 4/6 inhibitor against <i>RET</i>-fusion-positive non-small cell lung cancer cells
Takaaki Fujimura, Koh Furugaki, Naoki Harada, et al.
Leukemia & Lymphoma
|
August 7, 2023
Efficacy of retreatment with polatuzumab vedotin in combination with rituximab in polatuzumab vedotin-resistant DLBCL models
Natsumi Kawasaki, Mayu Tomita, Yoriko Yamashita-Kashima, et al.
Cancer Chemotherapy and Pharmacology
|
February 6, 2016
Antitumor activity of alectinib, a selective ALK inhibitor, in an ALK-positive NSCLC cell line harboring G1269A mutation: Efficacy of alectinib against ALK G1269A mutated cells
Yasushi Yoshimura, Mitsue Kurasawa, Keigo Yorozu, et al.
BMC Cancer
|
April 5, 2019
Expression of C-terminal ALK, RET, or ROS1 in lung cancer cells with or without fusion
Koh Furugaki, Marie Mochizuki, Mirei Kohno, et al.
Molecular Cancer Therapeutics
|
April 14, 2021
Obinutuzumab in Combination with Chemotherapy Enhances Direct Cell Death in CD20-Positive Obinutuzumab-resistant Non-Hodgkin Lymphoma Cells
Takaaki Fujimura, Yoriko Yamashita-Kashima, Natsumi Kawasaki, et al.
Journal of Clinical Psychopharmacology
|
September 16, 2006
Manic/hypomanic switch during acute antidepressant treatment for unipolar depression
Ken Wada, Takanobu Sasaki, Hiroaki Jitsuiki, et al.
NPJ Precision Oncology
|
October 25, 2023
FGFR blockade inhibits targeted therapy-tolerant persister in basal FGFR1- and FGF2-high cancers with driver oncogenes
Koh Furugaki, Takaaki Fujimura, Hayato Mizuta, et al.
Page
of 4